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Abstract   
 
Background 
The introduction of the X-pert MTB/Rif has shortened the time to detection of rifampicin 
resistant tuberculosis, which is assumed to be a surrogate for multidrug resistant 
tuberculosis. In practice, therefore MDR TB treatment is usually initiated soon after a 
rifampicin resistance result on X-pert MTB/Rif, simultaneously with a second sputum 
specimen, taken for confirmatory culture and further drug susceptibility testing. In this 
retrospective review, we report the outcome of further drug susceptibility testing performed 
on the second sputum specimen. 
Methods 
This study was based at the Klerksdorp Tshepong Hospital Complex. We retrospectively 
reviewed clinical files of patients admitted to the hospital MDR unit with rifampicin resistant 
TB on X-pert MTB/Rif between April 2011 and February 2014. Data from 384 patients were 
analysed. Only drug susceptibility testing result on the first sputum after admission was 
considered. 
Results 
Of 384 individual patient files with X-pert Rif resistance, MDR TB was confirmed in the 
subsequent culture isolates of 182(47.4%) patients (this means 176 on MTBDR plus and 6 
on phenotypic DST) and on raw sputa (MTBDR plus on a sputum smear) of 5(1.3%) 
patients. Therefore the total number of confirmed MDR TB cases was 187(49%). Rifampicin 
mono-resistance, isoniazid mono-resistance and drug sensitive TB were detected in 
137(36%), 12(3%) and 48(13%) patients respectively. Half [37/74(50%)] of patients with a 
CD4 count less than 50 cells/mm3 had rifampicin mono-resistance on culture and 4/74(5.4%) 
patients had isoniazid mono-resistance. Whereas patients with higher CD4 counts between 
50 and 350 cells/mm3, 58/181(32%) had rifampicin mono-resistance and 4/181(2.2%) had 
isoniazid mono-resistance (p-0.012). 
Conclusion 
Rifampicin resistance on X-pert MTB/Rif does not always mean multidrug resistant 
tuberculosis will be confirmed on sputum culture. Patients with lower CD4 counts who have 
rifampicin resistant TB on X-pert MTB/Rif may benefit from adding INH to the standardised 
MDR TB regimen while awaiting confirmatory tests to confirm or rule out MDR TB. 
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Protocol with extended literature review 
Background 
The World Health Organisation’s global report on tuberculosis estimates that 8.7 million 
incident cases of tuberculosis occurred in 2011 globally with most of the estimated cases 
occurring in Asia and Africa at 59% and 26% respectively; 0.5 million were children, 2.9 
million were women and South Africa was among the five countries with the largest number 
of incident cases at 0.4 million to 0.6 million cases1. It is worth noting that of the 8.7 million 
incident cases in 2011, 1.1 million (13%) were among people living with HIV and the highest 
proportion of these were in Africa1. Despite the overall decline in incident tuberculosis cases 
globally and in the Africa region shown in 2011, the incident tuberculosis cases were shown 
to be rising still in South Africa as a country1. There was an estimated 12 million prevalent 
cases of tuberculosis globally in 20111. Mortality rates from tuberculosis were also shown to 
have declined since 1990 both globally and regionally with forecast tuberculosis mortality 
rates expected to decline further in the period 2012- 2015 including in South Africa as a 
country1.  
A breakthrough in the treatment of tuberculosis was reached in 1943 when the first effective 
anti-tuberculosis agent, streptomycin was isolated2. In 1948, thiacetazone and para-
aminosalicylic acid, two new anti-tuberculosis agents came on the market2. Isoniazid was 
isolated in 1951, followed by pyrazinamide and cycloserine in 1952, ethionamide 1956, 
rifampicin 1957, and ethambutol 19622. However the advent of every new drug resulted in 
the selection of mutations conferring resistance to it2. For example, trials showed a rapid 
onset of isoniazid resistance among patients receiving monotherapy and suppression of 
resistance when isoniazid was given in combination with streptomycin or para-aminosalicylic 
acid2. Multiple drug regimens were therefore developed3.  
Multidrug resistant (MDR) tuberculosis is defined as the resistance of the mycobacterium 
tuberculosis (MTB) to both isoniazid and rifampicin4. The WHO global TB report showed that 
globally, there were an estimated 630 000 multidrug resistant (MDR) tuberculosis cases out 
of the 12 million TB prevalent cases in 20111. South Africa is one of the high burden 
multidrug resistant (MDR) tuberculosis countries with an estimated proportion of 1.8% (total 
325 321) of new tuberculosis( TB) cases being multidrug resistant (MDR) tuberculosis and 
6.7% ( total 45 915) of retreatment cases in 20115. The inpatient cost of multidrug (MDR) 
tuberculosis treatment per patient was estimated to be at more than 40 times the cost of 
drug susceptible tuberculosis6.   
Isoniazid (INH), only active against growing tubercle bacilli, is a pro drug that is activated by 
the enzyme called catalase peroxidase (KatG) encoded by katG gene and found in the 
mycobacterium tuberculosis (MTB)7. This activation results in the production of highly 
reactive species such as the isonicotinic-acyl radical or anion which then reacts with 
nicotinamide adenine dinucleotide [NAD(H)] and attacks the enoyl acyl carrier protein 
reductase (InhA enzyme) which is involved in mycolic acid synthesis7.  
Mutation in the KatG gene is the main mechanism of isoniazid (INH) resistance7. Resistance 
to isoniazid (INH) can also occur by mutations in the mabA/inhA promoter region causing 
over expression of the InhA enzyme or mutations in the InhA active site lowering InhA affinity 
to the isoniazid (INH)- nicotinamide adenine dinucleotide (NAD) adduct7.  
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Rifampicin, active against both growing and stationary phase bacilli, interferes with RNA 
synthesis of the mycobacterium tuberculosis (MTB) by binding to the beta subunit of the 
RNA polymerase7. Rifampicin resistance is conferred by spontaneously occurring mutations 
in the rpoB gene7.   
Mycobacterial cell wall also confers resistance to drugs through its low permeability given by 
its components such as mycolic acid, arabinogalactan and peptidoglycan7.   
Efflux pumps belonging  to different classes and present in the mycobacterium tuberculosis 
(MTB) have been shown to confer drug resistance by decreasing intracellular levels of 
drugs8. This mechanism of resistance is an object of study in the development of new 
drugs8.  
Mycobacteria also develop drug resistance through drug modifying enzymes such as the 
aminoglycoside 2’N-acetyltransferase described9.   
Previous tuberculosis (TB) treatment and default from treatment are important risk factors for 
drug resistance tuberculosis10, 11.   
On chest x-ray, studies have shown that in immune competent individuals, nodules, ground 
glass opacity and cavities are the predominant pattern in both extensively drug resistant and 
multidrug resistant tuberculosis20. On the other hand, immune compromised patients, 
especially those with very low CD4 T lymphocyte counts rarely present with cavities, but 
rather more commonly with hilar lymphadenopathies and consolidations in more than one 
lung zone21.  
Sputum smear microscopy is an important tool first developed in the 1880’s12. However, this 
technology only detects roughly half the number of active cases, it is highly operator 
dependant and takes days rather than hours to complete12. However, studies have shown 
that the sensitivity of smear microscopy is significantly lower in Human Immunodeficiency 
Virus (HIV) infected individuals than in HIV uninfected and those with unknown HIV status13.  
Culture of the mycobacterium tuberculosis, particularly in sputum sample, remains the gold 
standard for the diagnosis of both TB and drug sensitivity testing; the time period between 
sample collection and results availability depends on the culture medium used, up to seven 
days in liquid medium and up to 8 weeks in solid medium and a further 4-6 weeks for drug 
sensitivity testing (DST) with regard to the latter14.  
Drug sensitivity tests for tuberculosis are either phenotypic or genotypic15. 
Phenotypic  drug sensitivity testing is a method involving the culturing of the M. tuberculosis 
in the presence of anti-tuberculosis drugs in order to detect growth ( in terms of resistance) 
or inhibition( in terms of sensitivity)15. Direct phenotypic drug sensitivity testing involves the 
inoculation of a set of drug containing and drug free media with a concentrated specimen, 
whereas indirect testing involves inoculation of drug containing media with a pure culture 
grown from the original specimen15. The disadvantages of these methods are the time they 
take, technical complexity and the laboratory infrastructure they require15.  
Genotypic sensitivity testing involves detection of mutations that are responsible for drug 
resistance15. Examples are line probe assays that use PCR and reverse hybridization 
methods to detect rifampicin and isoniazid drug resistance15. The other type are beacon 
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assays that detect M. tuberculosis complex and associated rifampicin resistance directly 
from sputum samples using ultra-sensitive PCR15.  
The Genotype MTBDR plus is a commercially available molecular  line probe assay 
containing probes specific for mycobacterium tuberculosis complex and probes for common 
rifampicin resistance conferring mutations as well as isoniazid (INH) resistance conferring 
mutations16. It showed a sensitivity of 48, 4% in the detection of M. tuberculosis among 
MGIT culture positive sputa and a specificity of 98, 9% for culture negative sputa, these were 
found in the same study conducted in a South African gold mine16. The Genotype MTBDR 
plus showed a very low sensitivity in the detection of M. tuberculosis from smear negative 
sputa with higher sensitivity from smear positive sputa16. For specimens positive for M 
tuberculosis by MTBDR plus, this assay showed a higher sensitivity of 85,7% and specificity 
of 96,6% for rifampicin resistance as compared to a sensitivity of 62,1% and specificity of 
97,9% for isoniazid resistance, thus indicating that the sensitivity of genotype MTBDR plus 
depends on the bacillary burden16. However though the recent South African national data 
have shown that newer generation line probe assays are done off culture due to low smear 
positive rates22.  
X-pert MTB/RIF is an automated molecular test for Mycobacterium tuberculosis and 
resistance to rifampicin, it uses a semi nested real time polymerase chain-reaction assay to 
amplify an MTB specific sequence of the rpoB gene, which is probed with molecular 
beacons for mutations within the rifampicin-resistance determining region and it gives results 
within 2 hours17.  
In one review study of eighteen unique studies, the X-pert MTB/Rif achieved a pooled 
sensitivity of 88% and a pooled specificity of 98% when used as an initial test replacing 
smear microscopy18. As an add on test, following a negative smear microscopy, X-pert 
MTB/Rif achieved pooled sensitivity of 67% and pooled specificity of 98%18. For smear 
positive culture positive tuberculosis, the pooled sensitivity of X-pert MTB/Rif was 98%, and 
68% for smear negative culture positive tuberculosis18. The pooled sensitivity was 80% in 
people living with HIV, and 89% in people without HIV18. For rifampicin resistance detection, 
the X-pert MTB/Rif achieved a pooled sensitivity of 94% and a pooled specificity of 98%18. In 
the same study, it was estimated that the lower the prevalence of rifampicin resistant     
tuberculosis, the higher the probability of the X-pert MTB/Rif wrongly identifying patients as 
being rifampicin resistant18. This test is therefore very relevant to South Africa as it is among 
the high burden multidrug resistant (MDR) tuberculosis countries5.  
According to the national guidelines, patients suspected to have drug resistant pulmonary 
tuberculosis who test X-pert MTB/Rif positive rifampicin resistant should be treated as 
multidrug resistant (MDR) tuberculosis while another sputum specimen is collected for drug 
resistant tuberculosis confirmation19. Confirmation is achieved through both or either one of 
the two routes, the first one is conventional sputum for tuberculosis culture and drug 
sensitivity testing, the second one is smear microscopy if positive followed by the MTBDR 
plus but if smear negative , conventional culture and then the cultured bacilli are subjected to 
line probe assay19.  
At Klerksdorp Tshepong Hospital Complex, of the patients who were admitted with rifampicin 
resistance on the X-pert MTB/Rif test between April 2011 and March 2013, a certain 
proportion of them turned out to either be true multidrug resistant (MDR), mono-resistant or 
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sensitive tuberculosis. In this study, we retrospectively determine the true proportion of 
samples that are true multidrug resistant (MDR) and the contributing factors to this as well as 
the statistical significance this has in our setting  as this will influence our decision to treat or 
not to treat for multidrug resistant (MDR) tuberculosis when faced with rifampicin resistance 
on X-pert MTB/Rif.   
OBJECTIVES  
Overall aim  
1. To determine if rifampicin resistance on X-pert MTB/Rif test infers multidrug resistance 
(MDR) when compared to the gold standard tests genotype MTBDR plus or MGIT culture 
and sensitivity.  
Specific objectives  
a) To identify the proportion of positive MGIT culture with multidrug resistant (MDR) 
tuberculosis and multidrug resistance (MDR) identified on the MTBDR plus and compare 
them to that identified as rifampicin resistant by X-pert MTB/Rif test.   
b) To identify the proportion of samples that are positive for AFB on smear or negative for 
AFB out of all samples that tested positive for multidrug resistance on MGIT culture and 
sensitivity. c) To identify the proportion of mono-resistant and sensitive tuberculosis when X-
pert MTB/Rif diagnoses rifampicin resistance.  
  d) To evaluate if HIV sero-status and CD4 count impacts on X-pert MTB/Rif positivity rates  
METHOD  
We will conduct a retrospective, cross sectional study at Tshepong hospital, an 800 bed 
hospital with a 76 bed MDR/XDR tuberculosis unit situated in a mining district of Dr Kenneth 
Kaunda. A referral unit for the surrounding districts in the North West province. With a null 
hypothesis that all rifampicin resistance on X-pert MTB/Rif means MDR tuberculosis. The 
study will be conducted on male and female patients aged 13 years and above, of all races 
and socioeconomic background for a period between April 2011 and February 2014. 
 Eligible patients are those patients who were admitted to Tshepong MDR/ XDR TB unit from 
home or referred from surrounding hospitals with rifampicin resistance on sputum X-pert 
MTB/Rif test. As the main researcher, I will abstract data by paging through the clinical 
records of patients admitted to Tshepong MDR/ XDR TB unit during the period of study 
mentioned above. The clinical files will be obtained by visiting the Tshepong MDR/XDR TB 
unit and pulling files from the unit’s paper files, and abstracting will be done by filling in the 
printed data sheets so as to focus on obtaining variables mentioned above.  
In case of a file missing, I will make use of the backup electronic database compiled by the 
medical officer in charge of the Tshepong MDR/XDR TB unit whose permission I also have. 
In case some electronic information is still missing, I will  contact the referring hospital or 
local clinic or personally visit the institution concerned if it is within the Dr Kenneth Kaunda 
district. NHLS records will be accessed by myself electronically by entering specimen bar 
codes on to the old disa system or the new trackcare system depending on whether the 
sputum was taken before the new system was introduced or afterwards. I will then abstract 
the following variables from the NHLS: sputum expert MTB/Rif test result, smear and 
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microscopy result, phenotypic gold standard MGIT result, genotypic MTBDR plus result. 
Permission will be sought from the relevant authorities at NHLS and the Klerksdorp 
Tshepong Hospital complex prior to beginning this study.   
From a prelimianry look at the records at the Klerksdorp Tshepong Hospital complex prior to 
embarking on the drafting of the protocol, it appears that over 300 patients are admitted to 
the hosptial every year.   I plan to use the years from when the X-pert MTB/Rif was in use 
(mid 2011 – to the present). I will use data from June 2011 (when the X-pert was first 
routinely used to identify MDR TB at the site), and that I will include patients until February 
2014, over 1000 MDR patients will be available.  If only 30% were initially diagnosed by the 
X-pert MTB/Rif, conservatively it suggests there are 300 patients available for analysis.  
Assuming that 20% will have insufficient information (this is a retrospective study) then, 
conservatively, we will have approximately 240 patients for analysis.  Assuming that 30% are 
either rifampicin resistant only or false positive and have no resistance noted, then the 95% 
CI intervals of this point estimate (30%) generated will be 0.24-0.36.  
Similarly if 10%  are false positive rifampicin resistant the 95%CI around this point estimate 
are 0.06-0.14.   Both confidence intervals are sufficiently narrow for the purposes of this 
study. The sample size will be able to identify differences in proportions between sub groups 
at a prevalence of 0.1 and 0.3, respectively, or more at a power of 80 and alpha of 0.05.    
     
DATA ANALYSIS  
Data will be entered into the Microsoft excel spread sheet for cleaning and coding. Data 
cleaning will include looking for extreme cases, missing values and internal inconsistency. 
The Microsoft excel spread sheet will be imported to STATA version 12 for data analysis. 
For categorical variables frequencies and percentages will be computed and for numerical 
variables means and standard deviation will be calculated for normally distributed data, for 
abnormally distributed data median and interquartile ranges will be reported.   
Kolmogorov Smirnov tests will be used to test the distribution of data.  
Chi square test will be used to test for associations between two categorical variables for the 
first five specific objectives using contingency tables to represent them and determining the 
p value for each.  
We will use the t test to test for significance difference between normally distributed binary 
categorical variables.   
ETHICAL CONSIDERATIONS  
Since this will be a retrospective study, an informed consent will not be sought from patients 
and the names of the patients will not be displayed on the research report.  
An ethics approval will be sought from the ethics review panels at the university of the 
Witwatersrand, Tshepong hospital and the north west department of health.  
Study timing  
October 2013                                                           : Protocol submission  
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March to May 2014                                                       : Data collection and ethics application  
June 2014                                                                : Data analysis  
July to August 2014                                                  : Writing up of the report     
FUNDING  
Clinical records and results from the NHLS are those already done and paid for by the 
hospital.  
Stationary, traveling and electronic resources will be paid for by me, the main researcher.   
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Abstract   
Background 
The introduction of the X-pert MTB/Rif has shortened the time to detection of rifampicin 
resistant tuberculosis, which is assumed to be a surrogate for multidrug resistant 
tuberculosis. In practice, therefore MDR TB treatment is usually initiated soon after a 
rifampicin resistance result on X-pert MTB/Rif, simultaneously with a second sputum 
specimen, taken for confirmatory culture and further drug susceptibility testing. In this 
retrospective review, we report the outcome of further drug susceptibility testing performed 
on the second sputum specimen. 
Methods 
This study was based at the Klerksdorp Tshepong Hospital Complex. We retrospectively 
reviewed clinical files of patients admitted to the hospital MDR unit with rifampicin resistant 
TB on X-pert MTB/Rif between April 2011 and February 2014. Data from 384 patients were 
analysed. Only drug susceptibility testing result on the first sputum after admission was 
considered. 
Results 
Of 384 individual patient files with X-pert Rif resistance, MDR TB was confirmed in the 
subsequent culture isolates of 182(47.4%) patients (this means 176 on MTBDR plus and 6 
on phenotypic DST) and on raw sputa (MTBDR plus on smear) of 5(1.3%) patients. 
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Therefore the total number of confirmed MDR TB cases was 187(49%). Rifampicin mono-
resistance, isoniazid mono-resistance and drug sensitive TB were detected in 137(36%), 
12(3%) and 48(13%) patients respectively. Half [37/74(50%)] of patients with a CD4 count 
less than 50 cells/mm3 had rifampicin mono-resistance on culture and 4/74(5.4%) patients 
had isoniazid mono-resistance. Whereas patients with higher CD4 counts between 50 and 
350 cells/mm3, 58/181(32%) had rifampicin mono-resistance and 4/181(2.2%) had isoniazid 
mono-resistance (p-0.012). 
Conclusion 
Rifampicin resistance on X-pert MTB/Rif does not always mean multidrug resistant 
tuberculosis will be confirmed on sputum culture. Patients with lower CD4 counts who have 
rifampicin resistant TB on X-pert MTB/Rif may benefit from adding INH to the standardised 
MDR TB regimen while awaiting confirmatory tests to confirm or rule out MDR TB. 
 
Background 
Multidrug resistant tuberculosis is defined by resistance of the mycobacterium tuberculosis 
(MTB) to both isoniazid and rifampicin (Rif)1.  
 
INH resistance occurs more frequent than for most anti-TB drugs at a frequency of 1 in 
100000 to 1000000 bacilli in vitro2. Several gene mutations confer resistance to anti-
tuberculosis medications The more common mutation on the katG gene is a mechanism of 
isoniazid (INH) resistance2.  
 
Isoniazid, active against growing tubercle bacilli, is a pro-drug and is activated by the 
enzyme catalase peroxidase (katG), encoded by the katG gene found in MTB2. Activation 
results in the production of highly reactive species such as superoxide, peroxide, hydroxyl 
radical, nitric oxide and isonicotinic-acyl radicals2. The isonicotinic- acyl radical then reacts 
with nicotinamide adenine dinucleotide (NAD [H]) and attacks the enoyl acyl carrier protein 
reductase (InhA enzyme) which is involved in mycolic acid synthesis. 
 
Another mechanism of INH resistance occurs through mutations in the mabA/ InhA promoter 
region causing over expression of the InhA enzyme or mutation in the InhA active site 
lowering InhA affinity for the INH-NAD adduct2. 
 
Rif is active against both replicative and dormant bacilli, interferes with the ribonucleic acid 
(RNA) synthesis of MTB by binding to the beta subunit of RNA polymerase encoded by the 
rpoB gene2. Rif resistance is diagnosed by identifying mutations in the rpoB gene2. 
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Factors identified with increased risk for mutations and development of MDR TB include a 
history of prior treatment for TB, inadequate TB treatment such as monotherapy, addition of 
a single drug to a failing regimen and poor adherence to treatment3.  
 
 
 
TB and human immunodeficiency virus co-infection may increase the risk for drug resistant 
TB through malabsorption of anti- TB drugs possibly as a result of chronic diarrhoea or 
infection with cryptosporidium4-5. TB drug resistance may be primary (either transmitted from 
someone with drug resistant TB or newly acquired) or secondary resistance (resistant 
mutations are selected by inadequate TB treatment)6.  
 
Globally, the frequency of MDR TB is 3.3% among new cases (primary resistance) with the 
majority found in Eastern Europe and Asia1. The frequency of MDR TB among previously 
treated cases (secondary resistance) is 20%1.  In 2014, there was an estimated 480000 new 
MDR TB cases and approximately 190000 deaths from MDR TB worldwide1.In South Africa, 
the South African Tuberculosis Drug Resistance survey 2012-2014 reports that the national 
MDR TB rate was 2.8% with  MDR TB prevalence being 2.1% among new TB cases and 
4.6% among previously treated cases7.  
 
Of concern is the diagnostic gap where many MDR TB cases go undiagnosed1. This then 
implies more transmission of the resistant strains and poor outcome for undiagnosed cases.  
 
The recently developed End TB strategy calls for an early diagnosis of TB and universal 
drug sensitivity testing by 20351. 
 
Diagnosis of Drug Resistant TB 
TB DST can either be phenotypic or genotypic. Phenotypic DST involves the culturing of 
MTB in the presence of antibiotics with activity against TB8.  
 
Culture of the MTB remains the gold standard in diagnosis and determination of drug 
susceptibility of TB; culture on solid medium such as Lowenstein-Jensen slopes takes 
several weeks for an isolate to be positively identified as M tuberculosis with a further 4-6 
weeks for DST whereas culture on liquid medium (BACTEC mycobacterial growth indicator 
tube 960, BD, Sparks, MD, USA) may take up to seven days6.  
 
Genotypic DST detects mutations conferring resistance to rifampicin and isoniazid namely, 
mutations in the rpoB gene for rifampicin and mutations in the katG gene and InhA promoter 
region for INH9.It is tested in South Africa through the MTBDR plus (Hain Life science 
GmbH, Nehren, Germany). 
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Current diagnosis of MDR in South Africa uses a mix of molecular assays on raw sputum 
and molecular assays on culture isolates10. 
 
X-pert MTB/Rif (Cepheid Inc.) is an automated molecular test to detect MTB and rifampicin 
resistance, it uses a real time polymerase chain reaction to amplify the rpoB gene sequence 
which will be probed for mutations that confer rifampicin resistance11.   
 
In one review study of 18 unique studies, X-pert MTB/Rif- Cepheid Inc. achieved a pooled 
sensitivity of 88% and a pooled specificity of 98% when used as an initial test replacing 
smear microscopy12. 
 
As an add on test after a negative smear microscopy, X-pert MTB/Rif achieved a pooled 
sensitivity of 67% and specificity of 98%12. For smear positive culture positive sputum, 
sensitivity was 98% whereas it was 68% for smear negative culture positive sputum12. For 
rifampicin resistance detection, the pooled sensitivity was 94% with a specificity of 
98%12.The higher the prevalence of rifampicin resistance, the lower the probability of the X-
pert MTB/Rif wrongly identifying some cases as rifampicin resistant as compared to areas of 
low rifampicin resistance prevalence12. 
 
Discordant results between the X-pert MTB/Rif and drug susceptibility testing (phenotypic or 
genotypic) have been reported where rifampicin resistant MTB was detected on the X-pert 
MTB/Rif and rifampicin sensitive MTB was detected on DST, this occurrence prompted 
guidelines to be put in place by the World Health Organization (WHO) on doing confirmatory 
tests of drug resistance by using DST12.    
 
In South Africa there is little data reporting discrepancies between initial X-pert MTB/Rif 
assay and more definitive results of resistance assays on cultured isolates. Clearly accurate 
assessment with appropriate initiation of treatment are essential especially as MDR TB 
treatment is lengthy, expensive and is linked to severe adverse events some of which are 
irreversible13-14.  
 
 
We therefore conducted a retrospective study to determine the laboratory based resistance 
result on sputum in patients with rifampicin resistance diagnosed on a sputum X-pert 
MTB/Rif assay. We also examined associations between discordant results and patient 
characteristics. 
Objectives 
Overall objective 
12 
 
To determine the proportion of patients with rifampicin resistance on initial X-pert MTB/Rif 
whose subsequent routine clinic sputum drug sensitivity testing on arrival at the MDR Unit 
was resulted as: MDR, rifampicin mono-resistance or other drug resistance using routine 
public sector laboratory processing to assess rifampicin and isoniazid resistance (MTBDR 
plus and/or liquid culture drug susceptibility testing). 
Specific objectives 
In patients identified as having rifampicin resistance on X-pert MTB/Rif and treated at 
Tshepong Hospital drug resistant TB facility: 
 To report the proportion of MDR TB cases identified by subsequent phenotypic and 
genotypic (Hain Life science, GmbH, Nehren, Germany) drug susceptibility testing. 
 To determine the proportion of non-MDR TB results (INH mono-resistance, 
rifampicin mono-resistance and drug sensitive TB) and their characteristics. 
 To determine if HIV status and CD4 count are associated with DST outcome. 
Methods 
Tshepong hospital, located in Matlosana Municpality serving Klerksdorp and its surrounds, 
is a public sector hospital in the North West Province, South Africa. It has a dedicated drug 
resistant TB facility with 76 MDR beds. At the time of the study all patients with drug 
resistant TB were admitted to the facility for initiation of TB treatment and antiretroviral 
therapy if required. At the time of admission a baseline sputum sample was taken for 
confirmatory tests such as smear and microscopy, TB culture and drug sensitivity testing 
either on raw sputum (if smear positive) or on a cultured isolate by phenotypic and/or 
genotypic method. Other routine laboratory investigations are taken as required. 
 
Data including patient age, gender, date of admission, HIV status, CD4 count, HIV viral 
load, antiretroviral drug history, history of TB treatment, sputum X-pert MTB/Rif date, 
sputum culture collection date, incubation time, drug susceptibility testing results, chest X 
ray report, were abstracted from clinical files.  Sputum smear, mycobacterial culture and TB 
drug sensitivity. In cases where a patient had both phenotypic and genotypic drug 
susceptibility testing, only the phenotypic DST result will be considered for analysis 
because it is a gold standard test. 
 
Other results including CD4 counts and HIV viral loads were obtained from the National 
Health Laboratory Services (NHLS) records which link patient tests to a unique laboratory 
number. 
Three durations were collected: 
1. Inter-specimen interval: duration from initial diagnostic X-pert MTB/Rif to the 
collection of the sputum within the first week of admission from which DST was 
obtained 
2. Duration of TB treatment prior to sputum being taken for routine drug susceptibility 
testing 
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3. Time from specimen being placed in the liquid culture machine to the time the 
machine flagged the specimen as being culture positive (incubation time). 
We used the following definitions: 
1. MDR TB as MTB resistant to both INH and Rifampicin 
2. Rif mono-resistance (mono) as MTB resistant only to Rifampicin 
3. INH mono-resistance (mono) as MTB resistant only to INH 
4. Sensitive TB as MTB that is sensitive to both INH and Rifampicin 
5. Previous TB drug resistance detected as drug resistant TB diagnosed more than 2 
years ago 
6. Previous sensitive TB as sensitive TB diagnosed and treated for 2 months or more, 
more than a year ago 
Data on treatment and inpatient outcome were also captured.  
Patients aged at least 13 years admitted from the 1st of April 2011 to the 28th of February 
2014 with an X-pert MTB/Rif demonstrating rifampicin resistance were eligible for 
inclusion. Additionally patients had to have an initial drug sensitivity testing result either on 
raw sputum or on sputum positive culture isolate within 6 months of X-pert MTB/Rif result 
showing rifampicin resistance. 
Ethics approval 
The Human Research Ethics Committee (Medical) of the University of the Witwatersrand 
granted permission for this study to be conducted. 
Statistical analysis 
Descriptive statistics such as the frequency distribution, mean, and standard deviation 
were used to summarise data.  The mean was used to summarise metric variables such as 
patient age. Chi-square test of association was used to assess whether there was an 
association between two categorical variables such as drug sensitivity and HIV status. A 
Chi-square test p-value less than 0.05 is an indication that there is a significant relationship 
between the two variables while a  p-value of greater than 0.05 is an indication of no 
association between the variables. Independent sample t-test was used to compare the 
mean values for patient age by drug sensitivity group. A p-value less than 0.05 is an 
indication that there is a significant difference between the two means while a  p-value of 
greater than 0.05 is an indication of no significant difference between the mean values. 
Results 
In the period between the 1st of April 2011 and 28th of February 2014, a total of 650 
patients were admitted to the drug resistant TB facility with a positive X-pert MTB/Rif test 
showing rifampicin resistance referred by primary health care providers (local clinics or 
primary care hospitals). The distribution of admissions per year between the above 
specified dates was 74(2011), 224(2012), 276(2013) and 76(2014). 
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A total of 604/650(92.9%) files of patients who came to the facility with rifampicin resistant 
TB diagnosed on the X-pert MTB/Rif were reviewed for eligibility, files of 46 patients were 
not found. 
 
Of the 604 files with an initial X-pert MTB/Rif (GXP) reporting rifampicin resistance, two 
hundred and twenty (220) were excluded due to unavailability of drug resistance testing 
results, of whom 154 were untraceable, fifty six not done, eight patients had both sputum 
smear and culture negative, one grew a non-tuberculous mycobacterium (NTM) and one 
result was inconclusive. Data from 384 files was analysed (Figure 1). 
Demographics 
The average age of all patients was 36.74 years. There was no statistically significant 
difference in the average age across all categories of drug susceptibility test outcome (p-
0.076). See table 1. 
 
The majority of patients were HIV co-infected - 82% (315 patients) in this sample versus 69 
(18%) HIV negative patients. 
 
Of those with known CD4 count level, 181/312 (57.5%) had a count of 50-350 followed by 
74 (23.5%) patients with a count less than fifty; 57 (18.1%) had a CD4 count greater than 
350 cells/mm3. 
 
A total of 177 (56.2%) did not have a viral load taken because they were not on HAART on 
admission to the facility, for some, a viral load was not found. 
 
Virtually all [375(97.7%)] patients were sputum culture positive and in most [209 (55%)], 
the confirmatory sputum for culture was collected within two weeks of the initial X-pert 
MTB/Rif specimen and in most cases [199 (52.2%)], within 2 days of admission to the Unit. 
The median incubation time in the patients who were culture positive was 13 days (IQR 10 
days).  
At admission, based on the initial X-pert MTB/Rif result and history of prior TB treatment, 
primary drug resistant TB was diagnosed in 197 (51.3%) patients. 
   Proportion of MDR TB cases 
 MDR TB was confirmed in 187/384 (49%), most by genotypic drug sensitivity assays, six 
were confirmed on phenotypic drug sensitivity testing (DST) and of these six, four  had both 
genotypic and phenotypic DST, and there was a 100% concordance (they had MDR on both 
methods. (See figure 2 and table 2). 
Characteristics of non-MDR TB cases 
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Table 1 also shows that 51.3%(101/197) non-MDR TB cases versus 44.9%(84/187) MDR 
cases had a history of prior TB more than a year ago and the majority of them did not have 
drug resistant TB detected previously (p-0.018, p-0.497 respectively).  
The median incubation time in liquid culture for culture positive cases was 14 days for 
MDR cases, 14 days for rifampicin mono-resistant, 14 days for isoniazid mono-resistant 
and 12 days for sensitive TB cases. (Figure3). 
Table 3 shows a significant association between the level of the CD4 cell count and the 
confirmatory drug susceptibility testing in this study. Among cases with a CD4 count of less 
than 50 cells/mm3, the majority of them [50% (37/74)] had Rifampicin mono-resistant TB 
while the other half was distributed among MDR, INH mono-resistance and sensitive TB. 
Cases with a CD4 count of more than 50 cells/mm3 were shown to be more likely to have 
MDR TB with 56.9% (103/181) in the CD4 count of 50-350 cells/mm3 category and 50.9% 
(29/57) in the CD4 count more than 350 cells/mm3 having MDR TB respectively (p-0.002). 
Discussion 
Our data suggests that a rifampicin resistant TB result on the X-pert MTB/Rif test does not 
always infer that MDR TB is present when patients are investigated subsequently and 
sputum is subjected to drug susceptibility testing. Moreover, it appears from our data that 
patients with a CD4 count below 50 cells/mm3 were more likely to have rifampicin mono-
resistance on confirmatory drug sensitivity testing. 
In only half of patients with rifampicin resistance on X-pert MTB/Rif was MDR TB 
subsequently confirmed. This contrasts to a study by Dlamini-Mvelase et al from Kwa-Zulu 
Natal (KZN), where rifampicin resistance on X-pert correctly predicted MDR TB in 130/180 
(72.2%) patients when DST was done through MTBDR plus and in 81.4% when 
phenotypic DST was done15. 
Similarly, in Cape Town, Osman et al found that rifampicin resistance on X-pert MTB/Rif 
correctly predicted MDR TB in 88.6% of patients with genotypic DST (MTBDR plus) done 
on 159 patients and phenotypic DST for isoniazid resistance done on four patients16. 
Isoniazid mono-resistance was detected rarely in contrast to an initial report that isoniazid 
resistance is more common than rifampicin resistance17. This may be an under-estimate of 
the INH mono-resistant cases as the result is not a representation of all the mycobacterium 
tuberculosis cases because the entry point to this study was rifampicin resistance on the 
X-pert. The other reason for the under-estimate is that most of the confirmatory testing was 
reported on genotypic testing, therefore, other mutations that confer INH resistance may 
have not been covered by the test. 
The high prevalence of rifampicin mono-resistance significantly associated with a low CD 4 
count in this study agrees with observations made in the Western Cape and KZN of an 
emerging phenomenon of an increase in cases of rifampicin monoresistance18-19. 
A likely explanation may be malabsorption of TB drugs, especially of rifampicin in patients 
with diarrhoea and cryptosporidium as they showed that serum levels of rifampicin were 
lower than those of other anti-TB drugs measured after oral administration of these drugs, 
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although the study did not show that these patients developed MDR TB, malabsorption of 
anti-TB drugs may contribute to drug resistant TB20. 
Due to INH resistance being polymorphic, MTB DR plus has been shown to misdiagnose 
certain cases as INH sensitive21, hence the importance of phenotypic DST of all the INH 
sensitive cases to confirm or rule out sensitivity to INH. 
Limitations of this study include the fact that this is a retrospective study with missing data 
and lack of universal subjection of all specimens to both genotypic and phenotypic drug 
sensitivity testing as well as lack of information on resistance to second line anti-TB drugs 
due to the employment of the genotypic drug sensitivity testing. Another limitation is that 
for 210 cases, confirmatory drug susceptibility testing results were not available either 
because the specimen was lost or the test was not done, and this calls for improvement in 
the system of collection, transport, submission and tracing of the results as this will 
improve patient care.   
Conclusion 
 Rifampicin resistance on X-pert MTB/Rif does not always mean the patient has multidrug 
resistant tuberculosis. Our findings need to be confirmed in a prospective study involving 
other sites in South Africa. However, a large proportion of patients with rifampicin resistant 
TB on X-pert MTB/Rif who have rifampicin mono-resistance should continue to receive 
isoniazid as part of their treatment regimen while awaiting confirmatory culture and drug 
susceptibility testing, especially if their CD4 count is less than 50. 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
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Figure1.  Study diagram showing the number of X-pert MTB/Rif positive 
patients included and analysed in the study and their drug susceptibility 
outcome of initial confirmatory sputum. 
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Table1. Patient characteristics and drug susceptibility results in 384 
patients with initial X-pert MTB/Rif positive for rifampicin resistance. 
 
 
 
Variable Characteristic All Patients MDR Mono (Rif) Mono (INH) Sensitive P-Value 
 n= 384 187 137 12 48  
Age (years) mean years 36.74 37.12 37.58 30.50 34.42 0.076 
HIV Status 
Positive 315 (82.0) 154 (82.4) 114 (83.2) 11 (91.7) 36 (75) 
0.474 
Negative 69 (18.0) 33 (17.6) 23 (16.8) 1 (8.3) 12 (25) 
CD4 
< 50 
cells/mm
3 74 (23.5) 20 (13.0) 37 (32.5) 4 (36.4) 13 (36.1) 
0.012 
50 – 350 
cells/mm
3 181 (57.5) 103 (66.9) 58 (50.9) 4 (36.4) 16 (44.4) 
> 350 
cells/mm
3 57 (18.1) 29 (18.8) 18 (15.8) 3 (27.3) 7 (19.4) 
Unknown 3 (1.0) 2 (1.3) 1 (0.9) 0 (0.0) 0 (0.0) 
Viral Load 
< 2 log 1 (0.3) 0 (0.0) 1 (0.9) 0 (0.0) 0 (0.0) 
0.685 
2 >= 2 log 93 (29.5) 39 (25.3) 38 (33.3) 4 (36.4) 12 (33.3) 
Undetectable 44 (14.0) 20 (13.0) 19 (16.7) 1 (9.1) 4 (11.1) 
Not done 177 (56.2) 95 (61.7) 56 (49.1) 6 (54.5) 20 (55.6) 
HAART 
Yes 187 (59.6) 84 (54.5) 74 (65.5) 8 (72.7) 21 (58.3) 
0.105 No 124 (39.5) 70 (45.5) 36 (31.9) 3 (27.3) 15 (41.7) 
Unknown 3 (1.0) 0 (0.0) 3 (2.7) 0 (0.0) 0 (0.0) 
Defaulted 
HAART 
Yes 45 (23.6) 16 (18.8) 22 (28.6) 2 (25) 5 (23.8) 
0.708 No 145 (75.9) 69 (81.2) 54 (70.1) 6 (75) 16 (76.2) 
Unknown 1 (0.5) 0 (0) 1 (1.3) 0 (0) 0 (0) 
Previous TB 
Yes 185 (48.2) 84 (44.9) 80 (58.4) 6 (50) 15 (31.3) 
0.018 No 197 (51.3) 103 (55.1) 56 (40.9) 6 (50) 32 (66.7) 
Unknown 2 (0.5) 0 (0.0) 1 (0.7) 0 (0.0) 1 (2.1) 
Previous TB 
treatment 
default 
Yes 16 (8.6) 6 (7.1) 9 (11.3) 0 (0.0) 1 (6.7) 
0.809 No 169 (90.9) 79 (92.9) 70 (87.5) 6 (100.0) 14 (93.3) 
Unknown 1 (0.5) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 
Previous TB 
drug  
resistance 
detected 
Yes 7 (3.8) 2 (2.4) 5 (6.3) 0 (0.0) 0 (0.0) 
0.497 No 176 (95.1) 82 (97.6) 73 (91.3) 6 (100) 15 (100) 
Unknown 2 (1.1) 0 (0.0) 2 (2.5) 0 (0.0) 0 (0.0) 
Previous 
sensitive 
Yes 181 (97.8) 82 (97.6) 78 (97.5) 6 (100) 15 (100) 
0.539 No 2 (1.1) 2 (2.4) 0 (0) 0 (0) 0 (0) 
Unknown 2 (1.1) 0 (0) 2 (2.5) 0 (0) 0 (0) 
Interspecimen 
interval 
1 - 14 days 209 (55) 103 (55.4) 72 (52.9) 8 (66.7) 26 (56.5) 
0.673 > 14 days 127 (33.4) 61 (32.8) 45 (33.1) 3 (25) 18 (39.1) 
Unknown 44 (11.6) 22 (11.8) 19 (14.0) 1 (8.3) 2 (4.3) 
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Admission  to 
culture 
collection 
< 2 days 199 (52.2) 93 (49.7) 77 (56.6) 7 (58.3) 22 (47.8) 
0.256 >=2 days 139 (36.5) 73 (39) 40 (29.4) 4 (33.3) 22 (47.8) 
Unknown 43 (11.3) 21 (11.2) 19 (14.0) 1 (8.3) 2 (4.3) 
Sputum culture 
collection to 
positive result 
interval 
1 - 14 days 185 (48.2) 90 (48.1) 66 (48.2) 7 (58.3) 22 (46) 
0.777 > 14 days 140 (36.4) 69 (36.9) 50 (36.5) 4 (33.3) 17 (35.4) 
Unknown 45 (11.7) 22 (11.8) 20 (14.5) 1 (8.3) 2 (4.3) 
 Median(IQR) 13(10) 14(11) 14(10.25) 14(11.5) 12(10.75)  
Mycobacterial 
Culture 
Positive for M 
tuberculosis 
375 (97.7) 183 (97.9) 136 (99.3) 12 (100) 44 (91.7) 
0.046 
Negative 6 (1.6) 2 (1.1) 1 (0.7) 0 (0) 3 (6.3) 
Not done 
/Unknown 
2 (0.5) 2 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Lost 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1) 
Hain on 
culture_1 
MDR 176 (45.8) 176 (94.1) 0 (0) 0 (0) 0 (0) 
0.000 
Mono (Rif) 136 (36) 0 (0.0) 136 (1) 0 (0) 0 (0) 
Mono (INH) 12 (3.2) 0 (0.0) 0 (0) 12 (100.0) 0 (0) 
Sensitive 44 (11.6) 0 (0.0) 0 (0.0) 0 (0.0) 44 (91.7) 
Lost/ 
Unknown 
4 (1.1) 2 (1.1) 0 (0.0) 0 (0.0) 2 (4.2) 
Not done 3 (0.8) 1 (0.5) 0 (0.0) 0 (0.0) 2 (4.2) 
Auramine stain 
(Acid Fast 
Bacilli) 
Positive 243 (63.3) 114 (61) 84 (61.3) 10 (83.3) 35 (72.9) 
0.199 
Negative 141 (36.7) 73 (39) 53 (38.7) 2 (16.7) 13 (27.1) 
 Hain on raw 
sputum 
MDR 5 (1.3) 5 (3.7) 0 (0.0) 0 (0.0) 0 (0.0) 
0.000 
Mono (Rif) 1 (0.3) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 
Sensitive 4 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 4 (8.7) 
Not done 363 (97.3) 179 (97.3) 130 (99.2) 12 (100.0) 42 (91.3) 
Phenotypic 
DST 
 
MDR 6 (1.6) 6 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 
0.000 
Mono (Rif) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Sensitive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Not done 378 (98.4) 181 (96.7) 137 (100.0) 12 (100.0) 48 (100.0) 
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Figure2. MDR TB cases distributed according to the drug sensitivity testing 
method used. 
 
Table2. Results of confirmatory sputum TB drug susceptibility testing. 
Category Frequency Percent 
MDR 187 49% 
Mono (Rif) 137 36% 
Mono (INH) 12 3% 
Sensitive 48 13% 
Total 384 100% 
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Figure3. The median incubation time.  
 
 
 
Table3. Association between CD4 count and sputum drug susceptibility testing outcome.  
 
 
CD4 Total P - Value 
< 50 50 - 350 > 350     
MDR 20 (27.0) 103 (56.9) 29 (50.9) 152 (48,7)   
Mono (Rif) 37 (50.0) 58 (32.0) 18 (31.6) 
113 (36,2) 0,002 
Mono (INH) 4 (5.4) 4 (2.2) 3 (5.3) 11 (3,5)   
Sensitive 13 (17.6) 16 (8.8) 7 (12.3) 36 (11,5)   
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